Business Overview
INVO Fertility, Inc. is a healthcare services and technology company focused on expanding access to assisted reproductive technology (ART) care through acquiring and operating fertility clinics and distributing its proprietary INVOcell device. During the quarter ended March 31, 2026, the company completed its acquisition of Family Beginnings, an Indiana-based fertility clinic, expanding its clinic footprint to four locations while continuing to pursue a pipeline of additional acquisition opportunities. The company is strategically transitioning from a medical device company to a healthcare services company, with clinic operations now dominating commercial efforts while maintaining INVOcell distribution to third-party clinics.
Segment Performance
Fertility Clinics segment generated approximately $2.0 million in revenue for Q1 2026 versus $1.6 million in Q1 2025 (23% increase), driven by $0.3 million growth from the Georgia JV and $0.1 million from newly acquired Family Beginnings. Cost of services increased proportionally by $0.3 million (23%) to $1.3 million. INVOcell Device segment performance was not separately disclosed in revenue figures but remains a secondary part of current business focused on internal clinic usage and selected third-party distribution.
Forward Guidance
"Looking ahead, we expect our fertility operations to expand further, both through organic growth of our existing clinics and through the acquisition of additional, profitable fertility clinics." The company states it will "continue to work on growing INVOcell, both within our own clinics as well as to third party fertility clinics" and intends to "seek out additional, innovative technologies that we can utilize to benefit patients and enhance our clinic operations." Management notes expectations that "clinic operations will dominate our commercial efforts and revenue" and states the active acquisition pursuit is "aimed at accelerating our growth, building scale in our operations, and driving our overall business to cash flow break even and beyond to profitability."
